{"organizations": [], "uuid": "ccbf28d6296991a0368a85a73860d222b39a7eb3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-jounce-therapeutics-reports-q1-los/brief-jounce-therapeutics-reports-q1-loss-per-share-of-0-40-idUSASC0A0VP", "country": "US", "domain_rank": 408, "title": "BRIEF-Jounce Therapeutics Reports Q1 Loss Per Share Of $0.40", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T13:35:00.000+03:00", "replies_count": 0, "uuid": "ccbf28d6296991a0368a85a73860d222b39a7eb3"}, "author": "", "url": "https://www.reuters.com/article/brief-jounce-therapeutics-reports-q1-los/brief-jounce-therapeutics-reports-q1-loss-per-share-of-0-40-idUSASC0A0VP", "ord_in_thread": 0, "title": "BRIEF-Jounce Therapeutics Reports Q1 Loss Per Share Of $0.40", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "jounce therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9, 2018 / 10:36 AM / in 6 minutes BRIEF-Jounce Therapeutics Reports Q1 Loss Per Share Of $0.40 Reuters Staff\nMay 9 (Reuters) - Jounce Therapeutics Inc:\n* JOUNCE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS * Q1 LOSS PER SHARE $0.40\n* Q1 EARNINGS PER SHARE VIEW $-0.31 — THOMSON REUTERS I/B/E/S * Q1 REVENUE VIEW $15.1 MILLION — THOMSON REUTERS I/B/E/S\n* CONTINUES TO EXPECT CASH BURN ON OPERATING EXPENSES, CAPEX FOR 2018 TO BE APPROXIMATELY $80.0 MILLION TO $100.0 MILLION\n* EXPECTS TO RECORD APPROXIMATELY $50.0 MILLION TO $60.0 MILLION IN COLLABORATION REVENUE IN 2018\n* EXPECTS EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS TO BE SUFFICIENT TO FUND REQUIREMENTS FOR AT LEAST NEXT 24 MONTHS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-09T13:35:00.000+03:00", "crawled": "2018-05-09T13:49:24.017+03:00", "highlightTitle": ""}